


THE IMPACT OF IgA NEPHROPATHY (IgAN)

On the lives of patients and care partners in the US

WHY did we do this study?

We wanted to understand how people with IgAN and their care partners (caregivers) describe the impact of IgAN on their lives



Impact on the lives of people with IgAN

Impact on the lives of care partners

HOW did we do this study?

People with IgAN and their care partners completed an online survey



116 people with IgAN



116 caregivers (care partners)

- On average, 38 years old and living with IgAN for 6 years
- On average, 40 years old

The survey asked about the impact of IgAN on their daily lives and emotional well-being

It asked about their^a:

- Physical health
- Emotional well-being
- Ability to work
- Most bothersome symptoms



WHAT were the main results?



Impact on people with IgAN

Emotional well-being was negatively affected



Physical health was negatively affected



49% Almost half had depression^b

People with IgAN said the most inconvenient symptoms were

27% More than 1 in 4 felt anxious^b



About 3 in 4 had lower back pain

97% Most felt fear and uncertainty about the future



About 3 in 4 had constipation



Nearly 7 in 10 had bone or joint pain

Daily work was negatively affected



- Nearly 3 in 4 people with IgAN were employed
- People missed about 3 hours of work in a 40-hour week
- While at work, about a quarter of working time was negatively affected



Impact on care partners

Emotional well-being was negatively affected



36% More than 1 in 3 had depression^b

13% Around 1 in 8 felt anxious^b

99% Nearly all felt fear and uncertainty about the future

Daily work was negatively affected



- More than 9 in 10 care partners were employed
- People missed about 3 and a half hours of work in a 40-hour week
- While at work, about a quarter of working time was negatively affected

WHAT do these results mean?

IgAN can have negative effects on the daily lives and workplace productivity of people with this disease and the people who care for them

New treatments may help improve the lives of those affected by IgAN

This is a summary of a poster originally presented at the European Renal Association Congress in June 2023.¹

For more information, please visit ClinicalTrials.gov/NCT05200871.

^a Standard questionnaires used in this survey included those developed by researchers to assess kidney disease burden and symptoms, the impact of health on everyday life, anxiety, depression, and impacts on work and other activities.

^b Reflects proportion of people who reported moderate to severe symptoms of depression or anxiety. For comparison, in the general US population, approximately 1 in 14 adults report moderate to severe depression and approximately 1 in 17 adults report moderate to severe anxiety.²

References: 1. Szklarzewicz J, et al. The humanistic burden of rare kidney diseases: understanding the impact of immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) on patients and care-partners study (HONUS): updated results for IgAN in the United States (US). Poster presented at: 60th European Renal Association Congress; June 15-18, 2023; Milan, Italy and virtual. 2. Zablotsky B, et al. National Health Statistics Report. Assessing anxiety and depression: a comparison of National Health Interview survey measures. July 11, 2022.

